"Advanced breast cancer" trang 1 - tải miễn phí từ tailieuXANH
The impact of mammography screening programmes on incidence of advanced breast cancer in Europe: A literature review

The impact of mammography screening programmes on incidence of advanced breast cancer in Europe: A literature review
11    79    0
Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer

Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer
8    80    0
Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: Study protocol for a randomized controlled trial

Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: Study protocol for a randomized controlled trial
7    69    0
Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer

Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer
15    210    1
Assessment of preoperative axillary nodal disease burden: Breast MRI in locally advanced breast cancer before, during and after neoadjuvant endocrine therapy

Assessment of preoperative axillary nodal disease burden: Breast MRI in locally advanced breast cancer before, during and after neoadjuvant endocrine therapy
11    215    1
TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group

TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group
14    68    0
A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: A study protocol

A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: A study protocol
5    55    0
Incidence of advanced-stage breast cancer in regular participants of a mammography screening program: A prospective registerbased study

Incidence of advanced-stage breast cancer in regular participants of a mammography screening program: A prospective registerbased study
9    76    0
Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: A retrospective study

Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: A retrospective study
7    81    0
Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: An open-label, multi-center, non-comparative phase II study

Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: An open-label, multi-center, non-comparative phase II study
8    62    0
Phase II trial of eribulin mesylate as a firstor second-line treatment for locally advanced or metastatic breast cancer: A multicenter, single-arm trial

Phase II trial of eribulin mesylate as a firstor second-line treatment for locally advanced or metastatic breast cancer: A multicenter, single-arm trial
7    92    0
Final results from IMPROVE: A randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

Final results from IMPROVE: A randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer
12    62    0
Factors predicting patient satisfaction in women with advanced breast cancer: A prospective study

Factors predicting patient satisfaction in women with advanced breast cancer: A prospective study
7    73    0
Androgen receptor in advanced breast cancer: Is it useful to predict the efficacy of anti-estrogen therapy

Androgen receptor in advanced breast cancer: Is it useful to predict the efficacy of anti-estrogen therapy
8    99    0
Patterns of resource utilization and cost for postmenopausal women with hormonereceptor–positive, human epidermal growth factor receptor-2–negative advanced breast cancer in Europe

Patterns of resource utilization and cost for postmenopausal women with hormonereceptor–positive, human epidermal growth factor receptor-2–negative advanced breast cancer in Europe
12    74    0
Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2− advanced breast cancer in five European countries

Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2− advanced breast cancer in five European countries
15    55    0
Trastuzumab in advanced breast cancer – a decade of experience in Germany

Trastuzumab in advanced breast cancer – a decade of experience in Germany
9    60    0
Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: Activity and safety results from a phase II study

Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: Activity and safety results from a phase II study
10    63    0
Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: A randomized controlled trial

Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: A randomized controlled trial
13    47    1
Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: A multicenter retrospective study

Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: A multicenter retrospective study
10    88    2
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.